Kura Oncology, Inc.
Business
Kura Oncology is a biopharmaceutical company developing precision medicines for cancer treatment. It markets KOMZIFTI (ziftomenib), an FDA-approved menin inhibitor for relapsed or refractory NPM1-mutated acute myeloid leukemia, and develops small-molecule oncology candidates targeting cancer signaling pathways. Key pipeline programs include next-generation menin inhibitors and farnesyl transferase inhibitors for solid tumors including renal cell carcinoma and KRASG12C-mutated cancers. The company commercializes KOMZIFTI in the U.S. through a co-promotion agreement with Kyowa Kirin.
Summary from 10-K filed 2026-03-05
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Total revenue | 67 | 54 | 0 | — | — | |
| Cost of product sales | 57,000 | 0 | 0 | — | — | |
| Research and development | 251 | 170 | 115 | 93 | 85 | |
| Selling, general and administrative | 120 | 77 | 51 | — | — | |
| Total operating expenses | 371 | 247 | 166 | 140 | 131 | |
| Loss from operations | −304 | −193 | −166 | −140 | — | |
| Interest and other income, net | 27 | 23 | 15 | 4 | 1 | |
| Interest expense | −2 | −2 | −2 | −229,000 | — | |
| Total other income, net | 25 | 21 | 13 | 4 | 792,000 | |
| Loss before income taxes | −278 | −172 | −153 | −136 | — | |
| Income tax expense | 297,000 | 2 | 0 | 0 | — | |
| Net Loss | −279 | −174 | −153 | −136 | −130 | |
| Net loss per share, basic | −3.18 | −2.02 | −2.08 | −2.03 | −1.97 | |
| Net loss per share, diluted | −3.18 | −2.02 | −2.08 | −2.03 | −1.97 | |
| Weighted average number of shares used in computing net loss per share, basic | 88 | 86 | 73 | 67 | 66 | |
| Weighted average number of shares used in computing net loss per share, diluted | 88 | 86 | 73 | 67 | 66 | |
| Unrealized gain on short-term investments | 260,000 | 2 | 7 | — | — | |
| Comprehensive loss | −278 | −172 | −146 | −142 | −132 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 149 | 224 | 37 | 52 | 91 | |
| Short-term investments | 518 | 503 | 387 | 386 | 427 | |
| Accounts receivable, net | 9 | 2 | — | — | — | |
| Inventory | 413,000 | 0 | — | — | — | |
| Prepaid expenses and other current assets | 32 | 15 | 9 | 8 | 4 | |
| Total current assets | 709 | 745 | 432 | 446 | 522 | |
| Property and equipment, net | 8 | 2 | 2 | 3 | 3 | |
| Operating lease right-of-use assets | 7 | 6 | 7 | 4 | 6 | |
| Other long-term assets | 15 | 8 | 8 | 3 | 3 | |
| Total assets | 738 | 760 | 449 | 456 | 534 | |
| Accounts payable | 5 | 1 | — | — | — | |
| Accrued expenses and other current liabilities | 62 | 48 | — | — | — | |
| Current operating lease liabilities | 1 | 2 | 2 | 2 | 2 | |
| Current portion of long-term debt | 0 | 3 | — | — | — | |
| Current portion of contract liabilities | 49 | 24 | — | — | — | |
| Total current liabilities | 117 | 79 | 35 | 24 | 22 | |
| Long-term debt, net of current portion | 10 | 7 | 9 | 9 | — | |
| Long-term operating lease liabilities | 9 | 5 | 6 | 3 | 5 | |
| Other long-term liabilities | 3 | 2 | 705,000 | 265,000 | 375,000 | |
| Long-term contract liabilities | 425 | 254 | — | — | — | |
| Total liabilities | 564 | 347 | 52 | 36 | 27 | |
| Commitments and contingencies (Note 9) | — | — | — | — | — | |
| Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares issued and outstanding | — | — | — | — | — | |
| Common stock, $0.0001 par value; 200,000 shares authorized; 87,855 and 78,229 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 9,000 | 8,000 | 7,000 | 7,000 | 7,000 | |
| Additional paid-in capital | 1,347 | 1,308 | 1,120 | 997 | 941 | |
| Accumulated other comprehensive income | 1 | 764,000 | −1 | −8 | −2 | |
| Accumulated deficit | −1,174 | −895 | −721 | −569 | −433 | |
| Total stockholders' equity | 174 | 414 | 397 | 420 | 507 | |
| Total liabilities and stockholders' equity | 738 | 760 | 449 | 456 | 534 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Share-based compensation expense | 37 | 34 | 28 | 26 | 24 | |
| Amortization of premium and accretion of discounts on short-term investments, net | −8 | −13 | −9 | 2 | 4 | |
| Depreciation expense | 1 | 800,000 | 800,000 | 800,000 | 600,000 | |
| Non-cash interest expense | 515,000 | 523,000 | 477,000 | 73,000 | 399,000 | |
| Accounts receivable, net | −7 | −2 | 0 | — | — | |
| Inventory | −413,000 | 0 | 0 | — | — | |
| Prepaid expenses and other current assets | −16 | −7 | −2 | −3 | −357,000 | |
| Accounts payable | 4 | −2 | −924,000 | — | — | |
| Accrued expenses and other current liabilities | 13 | 17 | 11 | — | — | |
| Operating lease right-of-use and other long-term assets | −6 | 947,000 | −685,000 | 571,000 | −329,000 | |
| Other long-term liabilities | 1 | 758,000 | 137,000 | 184,000 | −20,000 | |
| Contract liabilities | 196 | 278 | 0 | — | — | |
| Net cash (used in) provided by operating activities | −64 | 134 | −125 | −110 | −105 | |
| Purchases of short-term investments | −762 | −659 | −410 | −271 | — | |
| Maturities of short-term investments | 755 | 558 | 426 | 304 | — | |
| Purchases of property and equipment | −7 | −472,000 | −168,000 | −626,000 | −1 | |
| Net cash (used in) provided by investing activities | −13 | −102 | 16 | 33 | −127 | |
| Proceeds from issuance of stock under equity plans | 2 | 9 | 1 | 4 | 4 | |
| Proceeds from issuances of common stock and pre-funded warrants, net of offering costs | 0 | 146 | 94 | 25 | — | |
| Net cash provided by financing activities | 2 | 154 | 95 | 39 | −3 | |
| Net (decrease) increase in cash and cash equivalents | −75 | 187 | −14 | −39 | −235 | |
| Interest paid | 998,000 | 1 | 1 | 73,000 | 784,000 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Kura Oncology, Inc.'s CIK number?
Kura Oncology, Inc.'s SEC CIK number is 0001422143 (1422143). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Kura Oncology, Inc.'s SEC filings?
All of Kura Oncology, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Kura Oncology, Inc. last report earnings?
Kura Oncology, Inc. (KURA) most recently filed an earnings 8-K with the SEC on May 12, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-219422). This is Kura Oncology, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Kura Oncology, Inc.'s most recent earnings 8-K?
Kura Oncology, Inc.'s latest earnings 8-K (Item 2.02) was filed May 12, 2026 under accession 0001193125-26-219422. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Kura Oncology, Inc.'s latest earnings 8-K →
Look up any company's CIK number →